A type-specific monoclonal antibody, LP10, precipitated a glycoprotein with a molecular weight of approximately 59,000 from purified herpes simplex virus type 1. Although this glycoprotein was similar in size to glycoprotein D (gD), it was shown to be less abundant in both virions and infected cells, to migrate more rapidly in its precursor form, to incorporate glucosamine but not mannose, and to have a more stable precursor in tunicamycin-treated cells than the gD precursor (pgD). Immunoassays of cells infected with insertion recombinants and intertypic recombinants localized the gene coding for the target antigen of LP10 to the unique short (Us) region at map units 0.892 to 0.924 excluding gD. The target antigen of LP10 was then definitively mapped to the Us4 open reading frame by immunoprecipitation of a polypeptide synthesized by in vitro translation of a Us4-specific transcript prepared by using an SP6 cloning vector and RNA polymerase. This newly identified glycoprotein product of the Us4 gene of herpes simplex virus type 1 is distinct from the previously identified gBl, gCl, gDl, gEl, and gHl.
It is certain that the surface glycoproteins of herpes simplex virus (HSV) play a major role in defining the biological and pathogenic properties of the virus, and it is assumed that the glycoproteins are the primary targets of the immune response after HSV infection (26) . Nevertheless, the glycoproteins of HSV remain poorly understood; we know little of their function, and the total number of glycoproteins specified by HSV is unknown. The existence of four HSV glycoproteins designated gB, gC, gD, and gE has been established for some time, and the nucleotide sequence of their corresponding genes has been determined (14; for a review, see reference 26). Marsden et al. (12, 13) identified a glycoprotein of HSV type 2 (HSV-2) which was distinguishable from gD and gE and which mapped in the unique short (Us) region of the HSV-2 genome. This probably corresponds to the polypeptide designated gG2 by Roizman et al. (22) . Showalter et al. (23) prepared monoclonal antibodies that reacted with a 110K glycoprotein of HSV-1. Further characterization of this glycoprotein and genetic mapping of its coding sequence in the unique long (Ul) region established that it is distinct from previously described HSV-1 glycoproteins, and it was designated gHl (3) .
The complete nucleotide sequence of the Us region of HSV-1 predicts the existence of yet further virus-specified glycoproteins (14) . In addition to the open reading frames representing sequences coding for gD and gE (Us6 and Us8, respectively), three other open reading frames (Us4, Us5, and Us7) probably code for transmembrane glycoproteins because their deduced translation products have characteristic signal peptides, membrane anchor sequences, and N glycosylation sites (14) . In this report we describe a type 1-specific monoclonal antibody, LP10, that precipitates a target antigen which is distinct from previously described HSV-1 glycoproteins on the basis of electrophoretic mobility and glycosylation and which maps to the Us4 open reading frame.
MATERIALS AND METHODS Cells. BHK21 clone 13 cells and HEp-2 cells were grown in Glasgow modified Eagle medium containing 10% tryptose phosphate broth and 10% newborn bovine serum in an atmosphere of 5% CO2 in air at 37°C.
Viruses. HSV-1 strain F (5) and HSV-2 strain 25766 (K. R. Dumbell, Wright-Fleming Institute, London) were used as control antigens in immunoassays. HSV-1 strain HFEM (31) was used as the inoculum for radioimmunoprecipitations. The insertion recombinant viruses were the generous gift of P. G. Spear (7) . The intertypic recombinant viruses were gifts from H. Marsden, and the determination of their genome structures has been previously reported (8, 12, 13) . For further fine mapping of intertypic recombinants, HSV-1 strain 17 (2) , and HSV-2 strains HG52 (27) and 333 (W. Rawls, McMaster University, Ontario, Canada) were used.
Radiolabeled antigens. Radiolabeled purified virus was prepared by replacing the medium from two confluent roller bottle cultures of HEp-2 cells with 55 ml of 5% Glasgow modified Eagle medium-95% methionine-free Dulbecco 21 ,000 rpm in an SW25 rotor of a Damon centrifuge at 4°C for 60 min. The pellet was suspended in 1 ml of phosphate-buffered saline (pH 7.4) containing 5% fetal bovine serum that had been heat inactivated at 56°C for 30 min, clarified at 34,000 rpm for 60 min, and filtered through a 0.22-,um membrane filter (Millipore Corp., Bedford, Mass.). This was then layered on a 30-ml 10 to 40% potassium tartrate gradient in phosphate-buffered saline-fetal bovine serum. The gradient was centrifuged in an SW25 rotor at 25,000 rpm at 4°C for 60 min. The band was harvested with a needle and syringe, diluted in phosphatebuffered saline-fetal bovine serum, and pelleted in an SW40 rotor at 34,000 rpm at 4°C for 60 min. The pellet, after suspension in 1 ml of phosphate-buffered saline-fetal bovine serum, contained 108.3 cpm and 108.9 PFU.
Radiolabeled infected cell lysates were prepared by infecting confluent BHK cell monolayer cultures in 6-cm dishes at a multiplicity of infection of 10 PFU per cell. For pulselabeling 2, 4, or 6 h after infection, the monolayers were washed twice with prewarmed phosphate-buffered saline and covered with 2 ml of prewarmed methionine-free Dulbecco modified Eagle medium containing 100 ,uCi of
[35S]methionine. The cells were harvested after 20 min of incubation at 37°C. For the prolonged labeling, cells were incubated in the radiolabel for the period of 2 to 8 h after infection. For the sugar labeling, reduced-glucose medium (0.9 g/ml) was used with 60 ,uCi of either D-[U-_4C]mannose (300 mCi/mmol; Amersham) or D-[1-14C]glucosamine (300 mCi/mmol; Amersham) per ml; 2.5 ,ug of tunicamycin (Sigma Chemical Co., St. Louis, Mo.) per ml was included in the labeled medium where indicated. The cells were lysed and harvested in RIPA buffer (50 mM Tris [pH 7.2], 150 mM NaCl, 1% sodium deoxycholate, 0.1% sodium dodecyl sulfate [SDS], 1% Triton X-100) plus 2 mM phenylmethylsulfonyl fluoride and 50 U of micrococcal DNase (Sigma) per ml.
Monoclonal antibodies. LP10 is an HSV-1-specific monoclonal antibody prepared as described by McLean et al. (15) . Preliminary immunoprecipitation experiments indicated that the target antigen was a glycoprotein of about 59,000 molecular weight, and reaction of the antibody with intertypic recombinants mapped the target gene to the Us region of the HSV-1 genome. On this basis the target antigen was tentatively identified as gD (3) . The antibody has no neutralizing activity in the absence or presence of complement. The antibody is of the immunoglobulin G3 (IgG3) class. The monoclonal antibodies to gG2 (AP1) and gHl (LP11) have been previously described (3, 12) . Monoclonal antibodies to the NP (5/1) and M (174/4) proteins of influenza A virus were the generous gift of K. van Wyke Coelingh, Bethesda, Md. (29) . The type 1-specific gD monoclonal antibody (11436) was a generous gift from P. Spear, Chicago, Ill. (7) . The specificities of AP10 (gE2) and LP6 (gC2) are based upon radioimmunoprecipitation and map position determined by using intertypic recombinants (A. Buckmaster, unpublished results).
Radioimmunoprecipitation. Radiolabeled infected cell lysates were clarified by centrifugation at 34,000 rpm for 1 12 .5% acrylamide-0.1% N,N'-methylenebisacrylamide resolving gels with 3% acrylamide-0.13% N,N'-methylenebisacrylamide stacking gels by using the SDSbuffer system of Laemmli (9) . The gels were then fixed, dried, and fluorographed (1) with Kodak X-Omat X51 film (Eastman Kodak Co., Rochester, N.Y.).
Immunoassays. The radioimmunoassay measured antibody bound to antigen fixed to microtiter plates, using for detection 125I-labeled staphylococcal protein A (Amersham) (12) . The enzyme immunofiltration assay measured antibody bound to antigen captured with a microtiter filtration device, using for detection a staphylococcal protein A-horseradish peroxidase conjugate (19) . The bound peroxidase was quantitated by the conversion of orthophenylenediamine to a colored product measured by absorbance (19 (24) . Blots were then hybridized with purified fragments from cloned subgenomic fragments of HSV-1 or HSV-2 DNA that were labeled with 32P by nick translation (20) , washed, and autoradiographed.
Molecular cloning of Us4 and Us7. The coding regions of Us4 and Us7 were subcloned from the BamHI J fragment of HSV-1 (see Fig. 6 ) into the plasmid vector pSP64 (PromegaBiotec, Madison, Wis.), which contains the SP6 RNA polymerase promoter (16) . Us4 was subcloned from the BamHI J fragment of strain SC16 cloned in pAT153. The 1.4-kilobase BamHI-NruI fragment from the 5' end of the BamHI J fragment was obtained after double digestion and then partially digested with Sau3A. The 1-kilobase Sau3A-NruI fragment (nucleotides 4111 through 5121) was harvested and inserted into the BamHI-SmaI site in the polylinker region of pSP64. The open reading frame of this fragment consists of nucleotides 4140 through 4854 of Us (14) .
Us7 was subcloned from the BamHI J fragment of strain Patton (generously provided by R. Watson [32] ) because this strain contains an NruI restriction enzyme site (starting at nucleotide 7157) which is not present in strain SC16 (32 (14) .
The restriction enzymes used in these studies were purchased from Boehringer Mannheim Biochemicals, Indianapolis, Ind.
In vitro transcription and translation. Purified DNA from cloned plasmids consisting of Us4 or Us7 in pSP64 was linearized with EcoRI. Capped transcripts were produced in 100-,ul reactions containing 40 mM Tris hydrochloride (pH 7.5), 6 mM MgCl2, 2 mM spermidine, 10 mM NaCI, 10 mM dithiothreitol, 100 U of RNasin (Anglian Biotechnology, Colchester, Essex), 500 ,uM each ATP, CTP, and UTP, 25 ,uM GTP, 500 ,uM 7-methylguanosine triposphate [m7G (5')pppG] (P-L Biochemicals, Milwaukee, Wis.), 2 jig of linearized DNA, and 20 U of SP6 RNA polymerase (Boehringer Mannheim). The reaction was incubated at 37°C for 2 h before one phenol extraction, one chloroform extraction, precipitation with ethanol, purification through a spin column of G-50 course Sephadex (11) , and reprecipitation in ethanol. The precipitate was dissolved in 6 p.l of diethylpyrocarbonate-treated water. Translation reactions (10 p.l) were performed as described in detail by Pelham and Jackson (17) trophoretically similar gD precipitated by LP2 (Fig. 2) . Cell lysates prepared from HSV-1-infected cells that were labeled for 20-min pulses with [35S]methionine and then immunoprecipitated with LP2 (lanes 6 through 8) revealed the glycoprotein precursor (pgD), which has been estimated to have a molecular weight of approximately 52,000 (4, 25) . polyacrylamide gel than did pgD (lanes 2 through 4). The estimated molecular weight of these bands was 48,000. Cell lysates prepared from HSV-1-infected cells that were labeled with [35S]methionine for a prolonged period (2 to 8 h postinfection) were immunoprecipitated with each of these two monoclonal antibodies. LP2 precipitated an additional heavier wide band (gD), which has an approximate molecular weight of 59,000 (Fig. 2, lane 5) . The additional band precipitated by LP10 was also wider and more slowly migrating than the pulse-labeled antigen. This heavier band migrated similarly to gD, but was much less intense (lane 1).
To determine whether the protein recognized by LP10 was a glycoprotein and to confirm further its nonidentity with gD, HSV-1-infected BHK cells were labeled for a prolonged period ( [14C]glucosamine either in the presence or in the absence of tunicamycin. The immunoprecipitates with LP2 or LP10 from these lysates were then characterized on 12.5% polyacrylamide gels and examined by fluorography (Fig. 3) (Table 1) .
Intertypic recombinants were used to define more precisely the genetic location in Us of the target antigen of LP10. Figure 4 compares the known type-specific composition of intertypic recombinant viruses and the type-specific antigens that they express. The LP10 target antigen segregated with gDl and away from gG2 in all recombinarits tested, but could be distinguished from gE [recombinants R12-1 and Bx6 (17-1)]. On the basis of these data the target antigen of LP10 was mapped between 0.892 and 0.924 map units excluding the gD gene.
Since the recombinant R12-1 specifies gDl and gE2, a recombination must occur between these two genes (Us6 and Us8). Since the type 1-specific LP10 reacts with R12-1, it was of interest to determine whether the Us7 coding region of this recombinant was derived from type 1 or 2. To map the crossover point more precisely, digests of DNA from R12-1 and the parental type 1 and 2 strains were made with various restriction enzymes. Southern blots were then hybridized with a 32P-labeled HindIII-NruI fragment derived from the BamHI J fragment of HSV-1 (Patton strain). This probe contains the coding region for gD and most of Us7 (Fig. 5 ). This analysis revealed that R12-1 contained the type 2 BamHI restriction site, but not the Sall site. The crossover therefore occurs near the C terminus within the gD coding region. These results support the hypothesis that Us7 in R12-1 is derived from type 2 and therefore is unlikely to be the target for LP10.
To define the 5' limit of the gene for the LP10 target antigen, the intertypic crossover from type 2 to type 1 in the (14) . The NruI site at nucleotide 7157 is specific to strain Patton (32) . Restriction enzyme abbreviations: B, BamHI; S3, Sau3A; Si, SphI; N, NruI; H3, Hindlll; Hi, HpaI. recombinant RD104 was examined. The region of uncertainty for the crossover is between the HSV-2 BgIII site and the HSV-2 HindIII site (12) . This area of uncertainty covers most of the Us3 and all of the Us4 and Us5 coding regions. LP10 reacts with RD104. It was therefore of interest to establish whether RD104 contains type 1 or type 2 DNA in the Us4 coding region.
The 32P-labeled probes used to analyze restriction enzyme digests were the HSV-1 BamHI-HindIII fragment and the HSV-2 BgIII-EcoRI fragment (Fig. 5) . After aligning the genomes of HSV-1 and HSV-2, the region of uncertainty for the crossover in RD104 could be narrowed slightly. The crossover was leftward of the NruI site between Us4 and Us5. RD104 therefore contains the type 1 coding region for Us5, but the type composition of Us4 was not ascertained.
Immunoprecipitation by LP10 of polypeptides synthesized, in vitro from Us4 and Us7. Reactions of LP10 with typespecific antigen expressed by intertypic recombinants implied that the gehe coding for the target antigen lay very close and probably 5' to the gD gene. Definitive genetic mapping, however, was not possible with the recombinants available, and mapping with this method is in any case prone to error due to the possible presence of undetected crossovers in intertypic recombinants. From the complete nucleotide sequence of the Us region of the HSV-1 genome, McGeoch et al. (14) identified two open reading frames, designated Us4 and Us7, which lie on either side of the gD gene (Us6) and whose deduced translation products have the properties of transmembrane glycoproteins (Fig. 6 ). These two coding regions were therefore each subcloned from the BamHI J fragment into the plasmid pSP64, which contains the promoter permitting the in vitro transcription of an inserted sequence by SP6 RNA polymerase. The resulting single-stranded RNA transcripts were then translated in vitro by using a rabbit reticulocyte lysate system (17) . LP10 specifically immunoprecipitated the [35S]methionine-labeled translation in vitro product from the Us4 coding region (Table 2) .
LP10 immunoprecipitated solely the polypeptide synthesized from Us4 when the translation products of Us4 and Us7 were mixed (Fig. 7) . The translation products of each open reading frame migrated as homogeneous bands. The estimated molecular weights of these products, with the migration of in vitro-synthesized influenza A virus polypeptides as standards, were 44,000 for Us4 and 52,000 for Us7. DISCUSSION LP10 is a nonneutralizing IgG3 mouse monoclonal antibody that immunoprecipitates a glycoprotein from purified HSV-1 virions and HSV-1-infected cells. Preliminary studies suggested that the target antigen of LP10 was gDl, based upon electrophoretic mobility and mapping the gene coding for the target antigen to the Us region by using intertypic recombinants. The autoradiographic signals produced by radioimmunoprecipitates with LP10 were weaker in 4 weeks than those produced with numerous monoclonal antibodies to gD in 2 days, thus prompting further investigation of the LP10 target antigen. As with gG2 and gHl, monoclonal antibodies permitted the identification of a glycoprotein whose recognition had been obscured by its comigration in gel electrophoresis with one of the previously identified and more abundant glycoproteins (3, 12, 22, 23) .
Both pulse-labeling and prolonged labeling of the LP10 target antigen with [35SJmethionine indicated similar kinetics, but much less abundant product than with gD. Although the larger, more slowly labeled form of gD and the LP10 target antigen found in virions and infected cells migrated similarly (approximately 59,000 daltons), the precursor form of target antigen migrated more rapidly (48,000 daltons) than pgD (52,000 daltons) in 12.5% polyacrylamide gels.
The use of insertion and intertypic recombinants permitted the mapping of the gene coding for the LP10 target antigen to a part of the Us region of the HSV-1 genome (map units 0.892 through 0.924 excluding the gD gene). McGeoch et al. (14) have deduced from their nucleotide sequencing of the Us region that there are five consecutive coding regions (Us4 through Us8), which have been confirmed by mRNA mapping (21) , that may code for glycoproteins. The products of two of these regions have been confirmed, gD (Us6) and gE (Us8). Consequently, to define precisely the gene coding for the LP10 target antigen we subcloned, transcribed, and translated in vitro Us4 and Us7, the sizes of which were consistent with the antigen in question. The polypeptide expressed in vitro from Us4 precipitated well with LP10, thus definitively mapping the LP10 target glycoprotein to Us4. Cytoplasmic vesicles were not included in the translation reaction, so that the polypeptide reacting with LP10 presumably underwent neither cleavage of a signal peptide nor glycosylation. It was fortunate for this study that such polypeptides expressed in vitro precipitated well with LP10 and with the monoclonal antibodies to M and NP proteins of influenza A virus. Only 1 of 7 monoclonal antibodies to gD precipitated the corresponding unprocessed polypeptide synthesized with the reticulocyte lysate system (10) .
The immunoprecipitated LP10 target antigen from HSV-1-infected cells and the product expressed in the reticulocyte lysate system from Us4 both migrated significantly more slowly than would have been predicted from the sequence of the Us4 open reading frame. The molecular weight of the unprocessed polypeptide deduced from the nucleotide sequence is 25,236 (14) . Using as molecular weight markers both influenza A virus polypeptides expressed in vitro and the published estimated molecular weights of pgD and gD (4, 24) , the following molecular weights were estimated for LP1O target antigens: polypeptide synthesized in vitro from Us4, 44,000; partially glycosylated precursor antigen from infected cells, 48,000; and final glycoprotein in virions and infected cells, 59,000. Similarly, the predicted molecular weight of the unprocessed polypeptide synthesized in vitro from Us7 is 41,366 (14) , although it migrated as a 52,000-molecular-weight protein in polyacrylamide gels. Comparable data were obtained by Lee et al. (10) , who selected mRNAs from HSV-1-infected cells with cloned viral DNA fragments and then translated these mRNAs with a reticulocyte lysate system. They mapped polypeptides of 42,000 and 55,000 daltons to what in retrospect were probably Us4 and Us7, respectively. The basis for this discrepancy between estimated molecular weights in polyacrylamide gels and deduced molecular weight is not understood. It should be noted, however, that for some proteins, migration distance may not be a simple function of molecular weight. It has already been observed that the estimated molecular weight of gG2 is 92,000 or 124,000 depending upon whether the polyacrylamide gel is cross-linked with N,N'-methylenebisacrylamide or N,N'-diallyltartardiamide, respectively (12) .
Similar discrepancies between the molecular weight deduced from nucleotide sequence and estimated by gel electrophoresis have been observed for gDl and gCl (6, 32) . This discrepancy was attributed to proline-rich polypeptides (43 of 394 for gDl, 63 of 523 for gC1), which would be expected to disrupt ot-helical structures (6, 32) . This explanation is consistent with the observed slow migration of the Us4 and Us7 polypeptides, the deduced amino acids of which are proline rich (34 of 238 for Us4 and 51 of 390 for Us7) (14) .
The LP10 target antigen incorporated [14C]glucosamine readily but little, if any, [14C]mannose. Tunicamycin, which inhibits N glycosylation (28) , blocked a significant amount of sugar incorporation. Either [35S]methionine or [14C]glucosamine was incorporated into a relatively homogenously migrating glycoprotein precursor, which was the sole or predominant form that incorporated radiolabel during 20-min pulses. With prolonged labeling (hours), an increase in apparent molecular weight to 59,000 was observed. This two-step glycosylation, the second step of which was inhibited by tunicamycin, has been observed with the previously described HSV glycoproteins (25) . The effect of tunicamycin also discriminates the LP10 target antigen from gD. We confirmed the observation by Pizer et al. (18) that gD precursors are extremely labile in tunicamycin-treated cells. Three potential N glycosylation sites (Asn-X-Thr or Asn-X-Ser) can be identified from the published nucleotide sequence of Us4. The partial inhibition of glucosamine incorporation by tunicamycin and the relatively poor incorporation of mannose suggest 0 glycosylation of this glycoprotein. The sequence also contains a potential N-terminal signal peptide and a C-terminal hydrophobic transmembrane region, which are characteristic of transmembrane glycoproteins (14) .
The newly identified glycoprotein is clearly distinct from the previously described glycoproteins of HSV-1 (gB1, gC1, gDl, gEl, and gH1) (3, 26) . We cannot yet give this glycoprotein an alphabetical designation. It is probable, but not certain, that this protein is the HSV-1 equivalent of gG2 which maps similarly in the Us region of the HSV-2 genome with the same intertypic recombinants used in this study (12) . LP10 and all of the gG2 monoclonal antibodies recognized at present are type specific. Homology or the lack of it between this newly identified HSV-1 glycoprotein and gG2 must await a type-cross-reactive monoclonal antibody or mapping and sequencing of the gene coding for gG2.
